Thomas Lester

Title: Innovations by Thomas Lester in Treating CLN2 Disease

Introduction

Thomas Lester is an accomplished inventor based in Castro Valley, CA (US). He has made significant contributions to the field of medical research, particularly in the treatment of Neuronal Ceroid Lipofuscinosis (CLN2) disease. With a total of 3 patents, his work focuses on innovative formulations and methods that aim to improve the lives of those affected by this condition.

Latest Patents

Lester's latest patents include formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for various methods of administration, including intrathecal, intracerebroventricular, or intraocular routes. These patents disclose methods of using rhTPP1 in the prevention and treatment of symptoms associated with CLN2 disease. The formulations and methods developed by Lester are effective in halting the progression of CLN2 disease and may be utilized to treat subjects who have CLN2 or a family history of the disease.

Career Highlights

Lester is currently associated with Biomarin Pharmaceutical Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on treating rare genetic disorders, showcasing his commitment to innovation in the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Saeed Moshashaee and Augustus O Okhamafe, who contribute to the collaborative efforts in research and development at Biomarin Pharmaceutical Inc.

Conclusion

Thomas Lester's innovative work in developing treatments for CLN2 disease highlights the importance of research in addressing rare medical conditions. His contributions through patents and collaboration with fellow researchers underscore the potential for advancements in medical science.